1. Home
  2. ELA vs IPHA Comparison

ELA vs IPHA Comparison

Compare ELA & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Envela Corporation

ELA

Envela Corporation

HOLD

Current Price

$25.97

Market Cap

619.2M

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

HOLD

Current Price

$1.76

Market Cap

189.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELA
IPHA
Founded
1965
1999
Country
United States
France
Employees
N/A
163
Industry
Consumer Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
619.2M
189.5M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
ELA
IPHA
Price
$25.97
$1.76
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$16.50
$5.75
AVG Volume (30 Days)
121.3K
134.2K
Earning Date
05-06-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
115.38
N/A
EPS
0.34
N/A
Revenue
$241,021,362.00
N/A
Revenue This Year
N/A
$180.36
Revenue Next Year
$22.54
N/A
P/E Ratio
$80.62
N/A
Revenue Growth
33.62
N/A
52 Week Low
$5.33
$1.18
52 Week High
$27.59
$2.63

Technical Indicators

Market Signals
Indicator
ELA
IPHA
Relative Strength Index (RSI) 63.23 55.75
Support Level $11.34 $1.72
Resistance Level $26.96 $2.32
Average True Range (ATR) 1.77 0.20
MACD 0.12 -0.01
Stochastic Oscillator 50.24 44.62

Price Performance

Historical Comparison
ELA
IPHA

About ELA Envela Corporation

Envela Corp is a provider of recycling and re-commerce services at the forefront of the circular economy. It operates through two segments, Consumer and Commercial Services. The Consumer segment, which generates key revenue for the company, predominantly buys to resell or recycle luxury hard assets like jewelry, diamonds, gemstones, fine watches, rare coins, and related collectibles, precious-metal bullion products, gold, silver, and other precious metals. The Commercial Services segment provides asset-disposition solutions to government agencies, middle-market firms, corporations, and other organizations.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: